DENVER – Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.
Lung cancer kills more people than breast, prostate, colorectal cancer combined. There are a number of treatment options now available for advanced NSCLC, the most common type of lung cancer, but almost all patients either fail or relapse after a period of clinical benefit. Patients that have relapsed or failed to respond to greater than two previous conventional chemotherapeutic treatments have very limited choices for further therapy.
A team of international investigators from 33 countries in Europe, North and South America, and Asia-Pacific conducted a relatively large phase III, randomized, double-blind, placebo-controlled trial comparing sorafenib plus best supportive care to best supportive care. This MISSION (Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer) trial was conducted to evaluate the efficacy and safety of sorafenib in the third or fourth-line setting with overall survival (OS) as the primary outcome measure, with PFS and other measures as a secondary endpoints.
The results published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, show that the median PFS was statistically increased in the sorafenib (N=350) vs placebo groups (N=353) (2.8 versus 1.4 months; hazard ratio [HR] 0.61; 95% confidence interval [CI] 0.51-0.72, p
Dr. Luis Paz-Ares, lead author on the study, commented that, "The improvement in PFS was modest and there was no improvement in OS, although an imbalance in post-treatment therapy may have played a role, with 56% of placebo patients and 44% of sorafenib patients receiving one or more post-treatment regimens. The biomarker results of this trial were intriguing, suggesting that EGFR mutation may be a predictive biomarker for the efficacy of sorafenib in patients with advanced NSCLC. However, our biomarker results should be interpreted with caution, since the subgroup of patients with available samples for biomarker analysis constituted only 47%, and was not representative of the overall study population. Additionally, post-study anti-EGFR TKI treatment was more frequently given to patients assigned to the sorafenib arm."
Co-authors Luis Paz-Ares, Vera Hirsh, Filippo de Marinis, James Chih-Hsin Yang, Heather A. Wakelee, Takashi Seto, Yi-Long Wu, Silvia Novello, Osvaldo Arén, Teng Jin Ong, Carol Peña, Egbert F. Smit, and Tony S. Mok are members of IASLC.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 4,000 lung cancer specialists in over 90 countries. Visit http://www.iaslc.org for more information.